of Work: Accurate risk assessment for carcinogens requires an understanding of the link between the presence of the chemical in human tissues and the resulting biological effects of the exposure. Sensitive techniques are needed to measure the effects of exposure and for studying genetic changes that may be directly in the pathway of the disease process. Previously we have developed methods to detect both exposure-induced expression of of CYP1A1 and the Bcl-2 t(14;18) translocation.
Aims : Develop biomarker technology for: 1) measuring the biological effects of exposure and early stages of disease; 2) detecting germline polymorphism; Accomplishments: 1)In order to detect early effects of TCDD exposure we used differential display to identify genes with altered expression. A novel TCDD induced gene (25-Dx) was cloned. Studies of 25-Dx expression suggest dose-dependent increase under both acute and chronic TCDD exposure. This gene is expressed in nearly all rat and human tissues and of particular interest is found in human sperm. Preliminary results suggest that the 25-Dx protein binds progesterone and is a membrane associated progesterone receptor coupled to a Ca signalling pathway. 25-Dx may be involved in TCDD's toxic reproductive effects. 2) An oligoligation based ELISA assay (OLA) for NAT1 polymorphisms was developed. Other OLAs are being developed. Automated sample handling equipment and high throughput genotyping procedures were implemented. The group is also developing new methods to assess damage from carcinogens. These studies seek to integrate environmental and genetic factors in understanding the etiology of human disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Intramural Research (Z01)
Project #
1Z01ES090604-01
Application #
6162327
Study Section
Special Emphasis Panel (LCBR)
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1997
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
Wang, Xuting; Tomso, Daniel J; Liu, Xuemei et al. (2005) Single nucleotide polymorphism in transcriptional regulatory regions and expression of environmentally responsive genes. Toxicol Appl Pharmacol 207:84-90
Lee, Su-Jun; Bell, Douglas A; Coulter, Sherry J et al. (2005) Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype. J Pharmacol Exp Ther 313:302-9
Liu, Xuemei; Campbell, Michelle R; Pittman, Gary S et al. (2005) Expression-based discovery of variation in the human glutathione S-transferase M3 promoter and functional analysis in a glioma cell line using allele-specific chromatin immunoprecipitation. Cancer Res 65:99-104
Grant, Delores J; Hall, Ingrid J; Eastmond, David A et al. (2004) Bilirubin UDP-glucuronosyltransferase 1A1 (UGT1A1) gene promoter polymorphisms and HPRT, glycophorin A, and micronuclei mutant frequencies in human blood. Mutat Res 560:1-10
Mammen, Jennifer S; Pittman, Gary S; Li, Ying et al. (2003) Single amino acid mutations, but not common polymorphisms, decrease the activity of CYP1B1 against (-)benzo[a]pyrene-7R-trans-7,8-dihydrodiol. Carcinogenesis 24:1247-55
Fritsche, E; Baek, S J; King, L M et al. (2001) Functional characterization of cyclooxygenase-2 polymorphisms. J Pharmacol Exp Ther 299:468-76
Grant, D J; Bell, D A (2000) Bilirubin UDP-glucuronosyltransferase 1A1 gene polymorphisms: susceptibility to oxidative damage and cancer? Mol Carcinog 29:198-204